Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05093309 · ClinicalTrials.gov registry record · NA
Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone
A NA study, sponsored by Auburn University.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
NCT05093309 is a NA study that has completed, run by Auburn University. The registered enrollment target is 55 participants.
The verdict
NCT05093309, a NA study, has completed, sponsored by Auburn University.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
Study Summary
Objectives: The purpose of this study was to assess the impact of the Empowering Community Pharmacists program on pharmacists' knowledge, perceived barriers, attitudes, confidence, and intentions regarding naloxone services implementation, as well as change in number of naloxone prescriptions dispensed. Methods: A 3-month pragmatic randomized controlled trial was conducted in 2018-2019. Alabama community pharmacists were recruited by email, phone, fax, and mailed postcards and randomized to intervention (monthly resources/reminders + educational webinar) or control (monthly resources/reminders + delayed educational webinar). Outcome measures were assessed via online surveys at baseline (T1), immediately post-intervention (T2), and 3-months post-intervention (T3), including: naloxone knowledge (percent correct); perceived barriers, attitudes, and confidence regarding naloxone services implementation (7-point Likert-type scale, 1=strongly disagree to 7=strongly agree); and number of naloxone prescriptions dispensed. Mean differences between control and intervention groups from T1-T3 were assessed using two-way mixed ANOVA and adjusted analyses were conducted using generalized estimating equations (GEE) with negative binomial distribution (alpha=0.05).
Interventions
- BEHAVIORAL Resources
- BEHAVIORAL Reminders
- BEHAVIORAL Educational Webinar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2018-09-18 |
| Est. Completion | 2019-09-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05093309
The ClinicalTrials.gov registry entry for NCT05093309 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Auburn University, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Resources is the first listed.
NCT05093309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05093309 about?
NCT05093309 is a clinical study titled "Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone". Objectives: The purpose of this study was to assess the impact of the Empowering Community Pharmacists program on pharmacists' knowledge, perceived barriers, attitudes, confidence, and intentions regarding naloxone services implementation, as well as change in number of naloxone prescriptions dispen...
What is the current status of trial NCT05093309?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2018-09-18. Estimated completion is 2019-09-18.
What interventions are being tested in trial NCT05093309?
The interventions under investigation include: Resources (BEHAVIORAL), Reminders (BEHAVIORAL), Educational Webinar (BEHAVIORAL).
Who is sponsoring clinical trial NCT05093309?
This trial is sponsored by Auburn University, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.